

ASK THE EXPERTS

EXPERTS DISCUSS GYNECOLOGIC CANCER RISK, PREVENTION AND TREATMENT



"FORCE improves the lives of the millions of individuals and families facing hereditary cancers.

FORCE Programs



Support

Personalized Peer Support

Virtual Support Groups

Private Facebook Group and Message Boards

Helpline




Advocacy & Public Policy

State & Federal Advocacy Efforts

Advocacy Day

Patient Advocate Leader Training

Take Action Campaigns



Education

Information on Genes & Hereditary Cancers

XRAY – Behind the Cancer Headlines

Educational Brochures & Decision Guides

Ask the Experts Webinar Series



Research

Research Matching and Targeted Study Promotion

Researcher Training, Assistance and Collaborations

Research Advocate Training

FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

Thank You to our sponsors!

Presenting Sponsor



Proprietary and Confidential. All Rights Reserved.

Thank You to our sponsors!

Empowerment Sponsors





FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

Thank You to our sponsors!

Affinity Sponsors







FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

Thank You to our sponsors!

Community Sponsors

FOUNDATION MEDICINE

Pfizer Oncology

EXACT SCIENCES

FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

Speakers



Melissa Frey, MD, MS

Gynecologic Oncologist

Weill Cornell Medicine

Breakout Room 1 - Risk, Detection & Prevention



Deanna Gerber, MD, MS

Gynecologic Oncologist


Weill Cornell Medicine


Breakout Room 2 - Treatment

Female Reproductive Tract

Focus of this webinar

- Ovaries
- Fallopian tubes
- Uterus





Definition

Ovarian cancer often refers to 3 related cancers that are treated in similar ways

- Ovarian cancer
- Fallopian tube cancer
- Primary peritoneal cancer

FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

Section 1

Gynecologic Cancer Risk

Genes Associated with Fallopian Tube and Ovarian Cancer Risk

Average lifetime risk for people without a mutation is about 1.1%

1. ATM (2-3%)
2. BRCA1 (39-58%)
3. BRCA2 (13-29%)
4. BRIP1 (5-15%)
5. EPCAM (8-38%)
6. MLH1 (4-20%)
7. MSH2 (8-38%)
1. MSH6 (1-13%)
2. PALB2 (3-5%)
3. RAD51C (10-15%)
4. RAD51D (10-20%)
5. SMARCA4* (Rare)
6. STK11* (Rare)


Genes Associated with Endometrial Cancer Risk

Average lifetime risk for people without a mutation is about 3%

1. EPCAM (21-57%)
2. MLH1 (34-54%)
3. MSH2 (21-57%)
4. MSH6 (16-49%)
5. PMS2 (13-26%)
6. PTEN (28%)
7. STK11 (9-10%)
8. BRCA1*
9. NTH1L**
10. POLD1**
11. POLE**

* BRCA1 has been linked to a rare but aggressive form of endometrial cancer

** More research is needed to prove a link between endometrial cancer and a mutation in these genes



Lynch Syndrome Genes

1. EPCAM
2. MLH1
3. MSH2
4. MSH6
5. PMS2

Proprietary and Confidential. All Rights Reserved.

FORCE
Facing Hereditary Cancer EMPOWERED


Section 2

Gynecologic Cancer Screening and Prevention

More Than Half of High Risk Individuals Were Not Told about Gynecologic Cancer Symptoms

N=831

Has a healthcare provider ever explained the symptoms to look for for endometrial, fallopian tube or ovarian cancer?



Proprietary and Confidential. All Rights Reserved.

FORCE
Facing Hereditary Cancer EMPOWERED



Symptoms of Gynecologic Cancers

Type body

Endometrial Cancer

Report symptoms below.

- Unusual vaginal bleeding or bleeding after menopause
- Pelvic or abdominal pain
- Bloating or abdominal distension
- Increased urinary frequency or urgency
- Pain during sex

Ovarian Cancer

Report symptoms below if persist more than 2-3 weeks and if they are a change from normal.

- Bloating
- Pelvic or abdominal pain
- Difficulty eating or feeling full quickly
- Urinary symptoms (urgency or frequency)


Proprietary and Confidential. All Rights Reserved.


FORCE
Facing Hereditary Cancer EMPOWERED

Female Reproductive Tract


Focus of this webinar

- Ovaries
- Fallopian tubes
- Uterus





Salpingectomy - Removal of the Fallopian Tubes



Gynecologic Cancer Risk Management

Cancer	Screening	Medication	Surgery
Endometrial	Endometrial biopsy Endometrial ultrasound (after menopause)	Progesterone-containing contraceptives (pills, injection, IUD)	Removal of the uterus (hysterectomy)
Ovarian & Fallopian Tube	None	Hormonal contraceptives (pills, patch, ring) containing both estrogen and progesterone	Removal of ovaries and tubes (salpingo-oophorectomy)

Proprietary and Confidential. All Rights Reserved.

FORCE
Facing Hereditary Cancer EMPOWERED

Ovarian Cancer Surgical Prevention Guidelines

Gene/s	Guidelines	Age to Consider Surgery	Notes
BRCA1, BRCA2, BRIP1, RAD51C, RAD51D	Recommend RRSO	Recommended age varies by gene and after childbearing is complete	Salpingectomy is an option for people not ready to remove their ovaries
EPCAM, PALB2, MLH1, MSH2	Consider RRSO	Varies by gene and after childbearing is complete	Salpingectomy is an option for people not ready to remove their ovaries or at time of hysterectomy for Lynch syndrome
ATM, MSH6, PMS2	More research needed, base decision on family history	Varies by gene and after childbearing is complete	Salpingectomy is an option for people not ready to remove their ovaries or at time of hysterectomy for Lynch syndrome

Proprietary and Confidential. All Rights Reserved.

Endometrial Cancer Surgical Prevention Guidelines

Gene/s	Guidelines	Age to Consider Surgery
EPCAM, MLH2, MSH2, MSH6	Consider hysterectomy with salpingectomy	After age 40 (or personalized based on childbearing plans)
PMS2	Consider hysterectomy with salpingectomy	Age 50
PTEN	Consider hysterectomy with salpingectomy	After childbearing is complete

Proprietary and Confidential. All Rights Reserved.

Decisions about Hysterectomy During RRSO for BRCA1 and BRCA2 Mutation Carriers

ELSEVIER

Gynecologic Oncology

Volume 206, March 2026, Pages 23-31




BRCA1 and *BRCA2* carriers: Perceptions of endometrial cancer risk

Mark E. Sherman [a], Laura Pacheco-Spann [a], Susan Friedman [b], Diane Rose [b], William D. Foulkes [c], Christopher C. DeStephano [d], Kristina A. Butler [e], Kathryn J. Ruddy [f], Zhihui Fang [g], Lauren E. Haydu [g]

Constituents received varying information about hysterectomy at the time of RRSO

If you consulted one or more surgeons about RRSO what were you told about having a hysterectomy? (N=280)



Early Detection Research Studies



The DETECT Study: Detecting Endometrial Cancer in Tampons

People planning to have a hysterectomy

bit.ly/force-detect-study

MiDE STUDY
The MicroRNA Detection Study

Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families (MiDE)

BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM

bit.ly/MiDestudy

FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

Risk-Reducing Salpingectomy with Delayed Oophorectomy Research



SOROCk Study

BRCA1 only

bit.ly/force-sorock



TUBA/WISP II Study

BRCA1, BRCA2, BRIP1, RAD51C, RAD51D

bit.ly/force-wisp2

FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

Section 3

Gynecologic Cancer Treatment

Genetic Testing in People with Endometrial or Ovarian Cancer

Endometrial Cancer

- Has an MSI-H or dMMR cancer
- Diagnosed before age 50
- Family history of endometrial or colorectal cancer before age 50
- Multiple family members with Lynch syndrome-related cancers

Ovarian Cancer

- Any person diagnosed with fallopian tube, ovarian or primary peritoneal cancer at any age should speak with an expert about genetic counseling and testing.

Types of Treatment for Ovarian and Endometrial Cancer

Treatment	Cancer
Surgery	Endometrial Ovarian
Chemotherapy	Endometrial Ovarian
Hormone therapy	Endometrial
Radiation therapy	Endometrial
Targeted therapy	Endometrial Ovarian
Immunotherapy	Endometrial Ovarian

Definitions

- **Platinum-sensitive** refers to cancer that responds to platinum-based chemotherapy and doesn't return for at least 6 months after finishing treatment.
- **Platinum-resistant** refers to cancer that returns or grows within six months of finishing treatment with platinum-based chemotherapy.

Proprietary and Confidential. All Rights Reserved.

Definition

Biomarker tests look for signs of cancer in your body, such as abnormal proteins, genes or cells.

Results can help detect cancer, guide treatment choices, and check how treatment is working.

Proprietary and Confidential. All Rights Reserved.

Liquid Biopsies for Cancer





Relevance: Medium-High

Most relevant for: People who have had or are considering liquid biopsy testing

Topic: What patients need to know about liquid biopsies in cancer care

Liquid biopsies are tests that look for signs of cancer in blood or other body fluids. These signs can include cancer cells that have broken away from a tumor, pieces of cancer cell DNA and proteins or other biomarkers found in cancer cells. Liquid biopsies can be used to screen for cancer before a cancer diagnosis or guide treatment after a diagnosis. (posted 2/6/26)

READ MORE ›

Definition

- **Maintenance therapy** refers to medication given after completing chemotherapy treatment to decrease the chance that the cancer will come back, or to delay the cancer from coming back.

Proprietary and Confidential. All Rights Reserved.

Definition

- **PARP inhibitors** are a type of targeted therapy used in ovarian cancer. They are most effective in people with a BRCA1 or BRCA2 mutation, however, they may be used to treat people with ovarian cancer who do not have a mutation.

Proprietary and Confidential. All Rights Reserved.

PARP Inhibitors for Gynecologic Cancer Treatment

Indication	Olaparib (Lynparza)	Rucaparib Rubraca	Niraparib (Zejula)
1st-line maintenance after complete or partial response to platinum chemo	X BRCA1/2 or HRD positive		X BRCA1/2 or HRD positive
2nd line or later maintenance therapy for stage 3 or 4 ovarian cancer	X BRCA1/2 positive	X BRCA1/2 positive	X BRCA1/2 positive
Endometrial cancer	Clinical trials only		Clinical trials only

Proprietary and Confidential. All Rights Reserved.

Other Biomarkers and Therapies for Ovarian and Endometrial Cancer

Biomarker	Drug	Indication
HRD	Lynparza (olaparib)	Ovarian
FRα-positive (folate receptor alpha)	Elahere (mirvetuximab soravtansine-gynx)	Ovarian
HER2-positive	Enhertu (trastuzumab deruxtecan)	Endometrial Ovarian
dMMR/MMR-D or MSI-High	Imfinzi (duvalumab) Jemperli (dostarlimab) Keytruda (pembrolizumab)	Endometrial Ovarian
pMMR/MMR-P	Lenvima (levatinib)	Endometrial
Minimally-Residual Disease (MRD) or Circulating Tumor DNA	No specific drug - used to monitor disease response or recurrence	Endometrial Ovarian

Immunotherapy for Endometrial Cancer

ELSEVIER

Annals of Oncology

Volume 35, Issue 5, May 2024, Pages 414-428



Review

Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer

Immunotherapy for Ovarian Cancer

FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

FORCE Endometrial Cancer Treatment Resources



Treatment

bit.ly/force-endometrial-treatment



Biomarkers

bit.ly/force-endometrial-biomarkers



Genetic Testing

bit.ly/force-endometrial-genetics

FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

FORCE Ovarian Cancer Treatment Resources

Treatment

bit.ly/force-ovarian-treatment

Biomarkers

bit.ly/force-ovarian-biomarkers

Genetic Testing

bit.ly/force-ovarian-genetics

FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

Clinical Trials Enrolling People with Endometrial Cancer



Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies

bit.ly/force-moma-341



Comparing an Experimental Drug Puxi-Sam with Standard Chemotherapy for Metastatic Endometrial Cancer (Bluestar-Endometrial01)

bit.ly/force-bluestar-endo-study

Clinical Trials Enrolling People with Ovarian Cancer



Comparing an Investigational Targeted Drug AZD5335 to Standard Treatments in People With Platinum-Resistant Ovarian Cancer (TREVI-OC-01)

bit.ly/force-trevi-oc1



Maintenance Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer with a BRCA Mutation or a Biomarker Called HRD

bit.ly/force-hrd-maintenance-study

Closing Thoughts

Thank You! Please Complete our Short Feedback Survey

bit.ly/ask-the-experts-gyn

Proprietary and Confidential. All Rights Reserved.

Join Us March 26 for our Next Hereditary Cancer Update

bit.ly/force-updates

Proprietary and Confidential. All Rights Reserved.



Connect with us

www.FacingOurRisk.org

866-266-RISK

Info@FacingOurRisk.Org

FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.